Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Jeffrey Gregg, MD, University of Nevada

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

All Issues

Molecular pathology selected abstracts

November 2024—Many people with an intellectual disability do not receive a molecular diagnosis following genetic testing. While 1,427 genes have been confidently identified as etiological for an intellectual disability (ID), all but nine of them are protein coding. To identify noncoding etiologies of ID, the authors conducted a genetic association analysis using whole genome sequencing data on 77,539 participants in the 100,000 Genomes Project. The study included 29,741 probands and 4,782 affected relatives assigned by expert clinicians to one or more of 220 specific disease classes encompassing a wide range of pathologies.

Q&A column

NOVEMBER 2024 Q. Our laboratory was cited for a deficiency because the manufacturer and methodology of our tumor marker assay was not available to clinicians. What is the reasoning behind this requirement? Read answer.
Q. For patients who have a hematocrit level greater than 55 percent, is it okay to use a CBC (hematocrit) that was not collected at the same time as the citrate sample? For example, can we use a CBC collected within 24 hours for an inpatient and a CBC from a previous visit for an outpatient? Read answer.

Newsbytes

November 2024—A picture may be worth a thousand words, but a conventional two-dimensional photograph of a surgical specimen can convey only so much information to a pathologist or surgeon. Overall geometry and margin status are difficult to interpret from static, single-perspective images.

Letters

November 2024—In “Lab test use: what 1 billion claims tell us” (August issue, page 1), you detailed the conclusions of a research study that analyzed insurance claims from effectively the entire U.S. adult population. The study found what it had sought, that 14.4 million individuals tested had undergone excessive laboratory testing, which is low-value care that poses patient risks and wastes resources. In reviewing the study data and analyses, I found that the methodology did not accurately estimate overuse and that the study overlooked the conclusion the data was screaming for: We are screening far too few people for chronic diseases and need to invest in access to care.

Put It on the Board

November 2024—The College of American Pathologists on Oct. 7 filed an amicus brief in support of the plaintiffs in the consolidated cases American Clinical Laboratory Association, et al., v. U.S. Food and Drug Administration, et al., and Association for Molecular Pathology, et al., v. U.S. Food and Drug Administration, et al. Plaintiffs in these consolidated cases challenge a final rule setting out the FDA’s plan to regulate LDTs as medical devices under the Federal Food, Drug and Cosmetic Act. “The Final Rule imposes draconian new restrictions—and crushing compliance costs—on the development and use of LDTs,” the CAP says in its amicus brief.

Harm or help? Maternal AFP race adjustments

October 2024—Using a race adjustment in maternal serum alpha-fetoprotein screening has physicians sitting on the fence these days. Including race in calculating risk for open neural tube defects has been a longstanding practice in medicine. Adjusting for higher rates of AFP levels seen in Black pregnant patients, proponents say, allows this population to receive equitable care. That premise lies on one side of the fence. On the other are those who maintain the practice is suspect, even harmful, and that the routine use of a race-based adjustment should stop. With the experience of dropping raced-based adjustments to estimated glomerular filtration rates still fresh in many minds, physicians are now deciding whether to keep or drop the adjustment for maternal serum AFP, even ahead of any potential changes to guidance by groups such as the CAP. Little wonder. Because as anyone who has ever sat on a fence knows, it can easily become a shaky, even painful, perch.

 

New system for hemolysis detection at point of care

October 2024—Werfen launched in July its Gem Premier 7000 with iQM3 blood gas testing system that for the first time makes hemolysis detection possible at the point of care. “Not having the capability to detect hemolysis at the point of care has been a gap in the field for quite a long time,” says Heather Stieglitz, PhD, D(ABCC).

For machine learning model use, turn to checklists

October 2024—Machine learning applications in molecular oncology testing are largely in the research or early clinical implementation phase, though some ML methods have been part of bioinformatics tasks for years, such as variant effect prediction.

Cyber safety and Epic installs: processes and problems

October 2024—Instrument assessments for cyber safety are in need of a fast track—or another solution to the delays they’re creating, say some Compass Group laboratory leaders. They met online on Sept. 3 with CAP TODAY publisher Bob McGonnagle, with whom they also talked about mergers and acquisitions and Epic Beaker transitions.

MARKETPLACE

TRENDING